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Abstract 
Purpose: A comprehensive molecular analysis was conducted to identify prognostic and predictive 
markers for adjuvant S-1 chemotherapy in stage II/III Japanese gastric cancer (GC) patients and to 
evaluate their potential suitability for alternative cytotoxic or targeted drugs. 
Experimental Design: We investigated genetic polymorphisms of enzymes potentially involved in 
5-fluoruracil (5-FU) metabolism as well as platinum resistance, previously identified genomic 
subtypes potentially predicting 5-FU benefit, and mRNA expression levels of receptor tyrosine 
kinases and KRAS as potential treatment targets in a single institution cohort of 252 stage II/III GC 
patients treated with or without S-1 after D2 gastrectomy. 
Results: 88% and 62% GC had a potentially 5-FU sensitive phenotype by SNP analyses of TS 3’UTR, 
and TS 5’UTR, respectively. 24%, 46%, 40%, 5%, and 44% GC had a potentially platinum sensitive 
phenotype by SNP analyses of GSTP1, ERCC1 rs11615, ERCC1 rs3212986, ERCC2, and XRCC1, 
respectively. High HER2, EGFR, FGFR2, or MET mRNA expression was observed in 49%, 66%, 72%, 
and 54% GC, respectively. High HER2 expression was the only significant prognosticator 
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(HR=3.912, 95%CI: 1.706-8.973, p=0.0005). High HER2 (p=0.031), low EGFR (p=0.124), high MET 
(p=0.165) RNA expression, and TS 5’UTR subtype 2R/2R, 2R/3C, or 3C (p=0.058) were significant 
independent predictors for S-1 resistance.  
Conclusions: The present study suggests that platinum-based or RTK targeted agents could be 
alternative treatment options for a substantial subgroup of Japanese GC patients currently treated 
with S-1. HER2, EGFR, MET, and TS 5’UTR SNP appear to be promising predictive markers for S-1 
resistance warranting validation in an independent GC series. 
 
Introduction 
Gastric cancer (GC) is the fourth most prevalent 
cancer and the third leading cause of cancer-related 
death worldwide (1). D2 gastrectomy is the mainstay 
of treatment for resectable GC in Japan (2), Europe 
and the US (3, 4). Two recent phase III trials in Eastern 
Asia demonstrated in patients with pathological stage 
II/III GC that adjuvant chemotherapy after D2 
gastrectomy improved overall survival compared to 
surgery alone changing clinical practice in Japan (5, 6).  
However, adjuvant S-1 chemotherapy does not 
seem to benefit all patients with stage II/III GC and 
severe or serious S-1 toxicity including anorexia, 
nausea, and diarrhea has been reported (5). 
Furthermore, 29% of ACTS-GC trial patients in the 
surgery plus adjuvant S-1 arm were not cured, 
whereas 61% of patients were cured by surgery alone 
(7) indicating that there is an urgent clinical need to 
(a) identify biomarkers that can better stratify patients 
for available treatment options than the currently 
used TNM stage after surgery and (b) to assess 
alternative treatment options such as other cytotoxic 
drugs (e.g. platinum) and/or targeted therapy. 
Several previous GC studies have attempted to 
identify predictive or prognostic markers for S-1 
chemotherapy. These studies included the 
investigation of protein expression of metabolic 
enzymes of 5-FU or folate such as thymidylate 
synthase (TS) (8-14), dihydropyrimidine 
dehydrogenase (DPYD) (8-10), orotate 
phosphoribosyl transferase (OPRT) (10-12, 14-16), 
thymidine phosphorylase (11, 13), or 
methylenetetrahydrofolate reductase (17, 18), the 
investigation of genetic polymorphisms of excision 
repair cross-complementing gene 1 (ERCC1) (17, 19, 
20), or the investigation of expression of EGFR (11, 17, 
21) or VEGF (22). However, all previous studies 
investigated usually only a small number of markers 
in each series and were often limited by the absence of 
a control group, small sample size, or use of a mixture 
of pre- and post-operative chemotherapy or resectable 
and unresectable disease. Furthermore, only two 
studies have investigated the relationship between 
biomarker and S-1 monotherapy (8, 21), while all 
other studies have used S-1 in combination with other 
cytotoxic drugs which may have influenced the 
results. 
The aim of the current study was (a) to conduct a 
comprehensive molecular analysis of potential 
prognostic and predictive factors for adjuvant S-1 
chemotherapy and (b) to evaluate the potential 
applicability of alternative cytotoxic or targeted drugs 
in a series of Japanese stage II/III gastric cancer 
patients treated with or without adjuvant S-1. Our 
analyses covered a wide range of biomarkers 
previously suggested to be related to benefit from S-1, 
5-FU or platinum based chemotherapy, such as gene 
polymorphisms of TS, OPRT, DPD, ERCC1, GSTP-1, 
and to potential benefit from receptor tyrosine kinases 
(RTKs) targeting therapy. 
Patients and Methods 
Patients 
This study was approved by the institutional 
review board of the Kanagawa Cancer Center, 
Yokohama, Japan. Gastric cancer patients were 
selected from a prospective database of the Kanagawa 
Cancer Center, Department of Gastrointestinal 
Surgery, Yokohama, Japan, according to the following 
criteria: (i) histologically proven gastric 
adenocarcinoma, (ii) curative gastrectomy as primary 
treatment between June 2002 and March 2010 
following Japanese gastric cancer treatment 
guidelines published in 2010 (2), (iii) pathologically 
stage II or III gastric cancer according to the 7th edition 
of the TNM classification (23), and (iv) availability of 
at least 5 years follow up data from all patients.  
A total of 252 patients were selected for this 
study. A flow diagram of patients involved in each 
analysis step is presented in Figure 1. Associations 
with clinicopathologic factors were examined in all 
patients (cohort 1, n=252), while 22 patients who 
received UFT instead of S-1 as adjuvant 
chemotherapy and 15 patients who received palliative 
S-1 chemotherapy due to peritoneal cytology positive 
were excluded from survival analyses (cohort 2, 
n=215). Survival data were obtained from hospital 
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records or from the Governmental registry system. 
The median follow-up period was 48.6 months (range 
3.3-136.7 months).  
Preparation of the specimen and pathological 
diagnosis 
Gastric cancer resection specimens were worked 
up according to the Japanese guidelines for gastric 
cancer (24). In addition, histological subtype 
according to the Lauren classification was 
determined. All slides from all resection specimens 
were reviewed by four senior gastrointestinal 
pathologists (HG, YM, TA, YK) to select and mark a 
representative block with the highest tumor cell 
density and a block with normal tissue for RNA and 
DNA extraction, respectively.  
DNA and RNA extraction 
DNA for polymorphism analyses was extracted 
from normal tissue (non-metastatic lymph nodes or 
normal gastric wall) using the QIAamp DNA Micro 
kit (Qiagen, Hilden, Germany) and quality controlled 
as described previously (25). RNA was extracted from 
tumor tissue block sections after microdissection 
using the High Pure RNA Paraffin Kit (Roche, 
Mannheim, Germany) according to the instructions of 
the manufacturer. The extracted RNA was quantified 
by a Nanodrop UV-Vis Spectrophotometer (Thermo 
Fisher Scientific, Waltham, MA) and 100 ng was used 
for the Nanostring assay.  
Analyses of polymorphisms 
DPYD, OPRT, ERCC1, ERCC2 and XRCC1 genotyping by 
MassARRAY 
Genotype analysis was performed using the 
MassARRAY iPLEX system (Sequenom, San Diego, 
CA) according to manufacturer’s instructions. A 
7-plex assay interrogating DPYD 
(A1627G7&IVS14+1G>A), OPRT (G638C), ERCC1 
(C118T&C8092A), ERCC2 (K751Q) and XRCC1 
(A399G) was designed using MassARRAY Online 
Design Tools (Sequenom) as described previously 
(26). Sample genotypes were determined by 
matrix-assisted laser desorption/ionization 
time-of-flight mass spectrometry (MALDI-TOF MS) 
analysis using the MassARRAY Compact system 
(Sequenom). The mass spectra analysis and genotype 
calls were generated using the Sequenom TYPER 4.0 
software. 
GSTP1 and TS 3’UTR genotyping by Sanger sequencing 
GSTP1 (I105V) and TS 3’UTR (agttcat variant) 
genotyping was performed by Sanger sequencing. 
Purified pellets were dissolved in Hi-Di Formamide 
(Life Technologies) and analyzed using an ABI PRISM 
3730 Genetic Analyzer (Life Technologies). 
Chromatograms were analyzed by SeqScape V2.5 
(Life Technologies) and manual review.  
TS 5’UTR genotyping by gel electrophoresis  
TS 5’UTR were investigated as described 
previously (27). For TS 5’UTR, the predominant 
alleles expected at TS 5’UTR are the 2R and 3R alleles. 
PCR products from 2R and 3R alleles differ by a single 
28 bp repeat, which can be resolved using gel 
electrophoresis. To determine the TS 5’ UTR 2R/3R 
genotypes, 10 µl of PCR product was purified by 4 µl 
of Exonuclease I (New England Biolabs) and 
Thermosensitive Shrimp Alkaline Phosphatase 
(Promega) mixture treatment. After Exo-TSAP 
purification, PCR products were digested with 1 µl 
HaeIII (10,000 units/ml, New 
England Biolabs) followed by 
electrophoreses in 4% agarose/1xTBE 
gel.  
Nanostring Assay 
A set of 203 genes selected based 
upon the molecular gastric cancer 
signature published by Tan et al (28) 
as well as other genes implicated in 
gastric carcinogenesis such EGFR, 
HER2, FGFR2, cMET and KRAS were 
selected for a customized Nanostring 
assay (Nanostring Technologies, 
Seattle, WA). The assay was 
performed according to the 
instructions of the manufacturer and 
the Nanostring workflow was 
employed for digital detection of 
expression counts for each gene. The 
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‘NanoStringNorm’ R package (version 2.15) was used 
to normalize the raw expression data adjusting for 
technical assay variations, background and RNA 
content. All samples flagged by the software were 
removed and the normalized expression data was 
used for all downstream analyses. 
Statistical analyses 
Tumors were classified based on their expression 
signature as G-INT/G-DIF using the nearest template 
prediction algorithm as described previously (28). For 
the current study, we employed two different 
classification schemes. First, tumors were classified 
into two subtypes e.g. G-INT or G-DIF. Secondly, 
tumors were classified into 3 subtypes e.g. G-INT or 
G-DIF or G-ambiguous.  
Associations between each biomarker and 
clinicopathological factors such as age, gender, 
location, tumor depth (pT), lymph node status (pN), 
distant metastasis (M), lymphatic channel invasion, 
blood vessel invasion, tumor size, macroscopic tumor 
type were examined in all patients. The analyses of 
the association between biomarker and histological 
subtype was restricted to those cases which were 
classified as either intestinal type or diffuse type GC. 
GC which were classified as mixed/unclassifiable 
according to Lauren (n=13) were excluded. 
Continuous factors (age, tumor size) were analyzed 
by student t-test, and categorical factors were 
analyzed by chi-square test. For analyses using 
distinct SNP subtypes, we excluded minor subtypes 
where the number of patients associated with a 
particular genotype (GG of GSTP1 in 5 patients and 
TT of ERCC1 rs3212986-C8092A in 10 patients) was 
felt to be too small for reliable statistical analysis. 
ERCC2 SNP was not analyzed for statistical analysis 
because most patients showed uniformal SNP type of 
TT (94.9%). 
For survival analyses, the gene expression level 
cut off (high expression versus low expression) was 
determined by the maximum chi-square method (29). 
The validity of the selected cut off point was 
confirmed by a two-fold cross-validation approach for 
multivariate analysis (30). Overall survival 
probability curves were calculated using the 
Kaplan-Meier method and compared by the log-rank 
test. For the analyses of prognostic factors, a Cox’s 
proportional hazard model was used to perform 
univariate and multivariate survival analyses in the 
surgery alone arm. A p-value of <0.05 was defined to 
be statistically significant for the analyses of the 
relationship of the biomarker with the 
clinicopathological factors including survival.  
For the test of predictive factors, the interaction 
of each biomarker with S-1 treatment in the Cox’s 
proportional hazard model was analyzed in the 
surgery alone and the surgery+S-1 arm. As this was a 
post hoc analysis that may not have enough power to 
detect an interaction effect, a raised significance level 
of p<0.2 was used to classify an interaction as being 
significant (31).  
Results 
Table 1 shows the clinicopathological 
characteristics by treatment and cohort. Cohort 1 (all 
patients) was used for the analysis of the biomarker 
frequency and association with clinicopathological 
analyses, cohort 2 (excluding patients who received 
adjuvant chemotherapy other than S-1) was used for 
the prognostic and predictive analyses. As expected, 
patients in the surgery+S-1 group had cancers with 
higher pT category, higher TNM stage, larger tumor 
size, and were more frequent of scirrhous 
macroscopic tumor type (all p-values < 0.05). 
Although there was no statistically significant 
difference in overall survival (OS) between the 
surgery alone and surgery+S-1 group by log-rank test 
(p=0.177) in our series, the hazard ratio for 
surgery+S-1 chemotherapy was 0.694 (p=0.196) in 
multivariate analysis which was similar to that 
observed in the ACTS-GC trial (5). 
Frequency of biomarkers and association with 
clinicopathological factors  
SNP genotypes suggested to predict 5-FU 
resistance e.g. TS 3’UTR (+6bp/-6bp and -6bp/-6bp) 
and TS 5’UTR (2R/3G, 3C/3G, and 3G/3G) were 
found in 88% and 62% GC, respectively. SNP 
phenotypes suggested to predict 5-FU toxicity e.g. 
OPRT (GC+CC) and DPYD (AG+GG) were present in 
36% and 48% GC, respectively, while those suggested 
to predict platinum sensitivity e.g. GSTP1 (AG+GG), 
ERCC1 rs11615 (CT+TT), ERCC1 rs3212986 (GT+TT), 
ERCC2 variant (GT), and XRCC1 rs25487 (AG+GG) 
were present in 24%, 46%, 40%, 5%, and 44% GC, 
respectively. High HER2, EGFR, FGFR2, or MET RNA 
expression identifying GC patients potentially 
benefitting from targeted therapy, was observed in 
49%, 66%, 72%, and 54% GC, respectively.  
DPYD2A was associated with the presence of 
distant metastasis (p=0.040). GT type of ERCC1 and 
AA type of XRCC1 were associated with distal 
location of the cancer (p=0.018) and female gender 
(p=0.043), respectively. The [+6bp/-6bp] type of TS 
3’UTR and [2R/3C] or [3C/3C] type of TS 5’UTR were 
associated with younger age (p=0.022 and p=0.008, 
respectively). No other associations between 
individual SNP biomarker status and 
clinicopathological factors were seen. 
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Table 1. Clinicopathological characteristics of patient cohort 1 
(n=252) and patient cohort 2 (n=215; excluding 22 patients 
treated with UFT adjuvant chemotherapy and 15 patients who had 
positive peritoneal cytology and received palliative S-1 
chemotherapy (*)) 
 Surgery 
alone 
Surgery + S-1 
n %  n / n* %/ %*  
Age Median (range) 
years 
66 (35-85) 64 (35-83) 
64 (35-80)* 
Gender Male 74 68.5 102 / 73 70.8 / 68.2 
Female 34 31.5 42 / 34 29.2 / 31.8 
Tumor location Upper third 29 26.9 47 / 35 32.6 / 32.7 
Middle third 41 38 62 / 48 43.1 / 44.9 
Lower third 38 35.2 35 / 24 24.3 / 22.4 
Tumor size Median (range) mm 50 (15-180) 60 (25-212) 
60 (28-212)* 
Macroscopic tumour 
type 
0 25 23.1 14 / 10 9.7 / 9.3 
1 6 5.6 7 / 6 4.9 / 5.6 
2 26 23.1 36 / 26 25.0 / 24.3 
3 28 26.9 37 / 24 25.6 / 22.4 
4 2 1.9 18 / 16 12.5 / 15 
5 21 19.4 32 / 25 22.3 / 23.4 
Depth of invasion (pT) T1/T2 31 28.7 18 / 16 12.5 / 15 
T3/T4 77 71.3 126 / 91 87.5 / 85 
Lymph node status (pN) N0 20 18.5 22 / 19 15.3 / 17.8 
N1/N2/N3 88 81.5 122 / 88 84.7 / 82.2 
 TNM stage 2A 18 16.7 8 / 5 5.6 / 4.7 
2B 36 33.3 36 / 31 25.0 / 29 
3A 25 23.1 18 / 11 12.5 / 11.2 
3B 14 13 29 / 25 20.1 / 22.4 
3C 15 13.9 53 / 35 36.8 / 32.7 
Lymphatic invasion negative 42 38.9 45 / 39 31.3 / 36.4 
positive 66 61.1 99/ 68 68.7 / 63.6 
Venous invasion negative 29 26.9 34 / 32 23.6 / 29.9 
positive 79 73.1 110 / 75 76.4 / 70.1 
Histological tumor type Intestinal 40 37.4 42 / 34 29.1 / 31.8 
Diffuse 62 57.4 95 / 67 66.0 / 62.6 
unclassifiable 6 5.5 7 / 6 4.9 / 5.6 
 
Second, we examined associations between 
clinicopathological factors and gene expression, either 
at the single gene or gene signature level. High EGFR 
and high FGFR2 RNA expression were associated 
with younger age (p=0.02 and p=0.01, respectively). 
High EGFR, low HER2 and high FGFR2 RNA 
expression were associated with diffuse type 
histology (p=0.001, p=0.009 and p=0.016, 
respectively). High FGFR2 was associated with 
increased frequency of vascular invasion (p=0.047), 
high MET with distal location of the cancer (p=0.012) 
and low KRAS with presence of distant metastasis 
(p=0.022).  
125 patients (51%) were classified as G-INT and 
120 patients (49%) as G-DIFF when the two-category 
classification was employed. When the three-category 
classification was used, 88 (35.9%) patients were 
classified as G-INT, 71 (29%) patients as G-DIFF, and 
86 (35.1%) patients as G-ambiguous. G-DIFF was 
associated with higher pT category (e.g. deeper 
invasion of the primary tumor) compared to G-INT or 
G-ambiguous type.  
Association of biomarker status and patient 
prognosis  
In order to distinguish between predictive and 
prognostic value of a biomarker, associations with 
survival were analysed separately by treatment e.g. 
the prognostic value of a marker was determined 
using data from the surgery alone treated patient 
group. For multivariate overall survival analyses, 
TNM stage, tumor size and macroscopic tumor type 
were included in the model together with the 
biomarker of interest. The results of the survival 
analyses are illustrated using a Forest plot of hazard 
ratios (Figure 2). High HER2 RNA expression was 
associated with poor survival and was the only 
significant independent prognosticator (HR=3.912, 
p=0.0005). Patients with TS 5’UTR 2R/3G or 3C/3G 
or 3G/3G tended to have poorer survival than those 
with 2R/2R, 2R/3C, or 3C/3C (HR =2.185, p=0.058) 
but the difference did not reach statistical significance.  
Association of biomarker status and patient 
benefit from adjuvant S-1 chemotherapy  
To identify biomarkers that might predict which 
GC patient subgroup will benefit from adjuvant S-1 
therapy, we determined the interaction of each 
biomarker with S-1 treatment using a Cox’s 
proportional model by including S-1 treatment, TNM 
stage, tumor size, macroscopical tumor type, and 
biomarker in the model. The results are illustrated in a 
Forest plot of hazard ratios (Figure 3). We found that 
TS 5’UTR subtype 2R/2R, 2R/3C, or 3C/3C (p=0.058), 
high RNA expression of HER2 (p=0.031), low EGFR 
expression (p=0.124) and high MET expression 
(p=0.165), were significant independent predictors for 
S-1 resistance.  
Discussion 
The present study reports our comprehensive 
analysis of prognostic and predictive biomarkers in a 
cohort of Japanese gastric cancer treated by surgery 
with and without adjuvant S-1 chemotherapy. S-1 is a 
drug which consists of tegafur, a prodrug of 5-FU, 
gimeracil, a competitive inhibitor of DPYD, and 
oteracil potassium, an inhibitor of 5-FU 
phosphorylation. We explored a number of different 
biomarkers including (i) genetic polymorphisms of 
enzymes involved in 5-FU metabolism such as OPRT 
(15), DPYD (32), and TS (33), (ii) genetic 
polymorphisms of proposed predictors for platinum 
resistance (34, 35) such as GSTP-1, ERCC1, and 
XRCC1, (iii) previously identified GC genomic 
subtypes (G-INT and G-DIFF (28)) as potential 
prognosticators as well as predictors for 5-FU 
sensitivity and (iv) RNA expression of EGFR, HER2, 
FGFR2, MET, and KRAS to evaluate the potential for 
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therapies targeting the RTK/KRAS signaling pathway 
in Japanese gastric cancer currently treated with 
surgery plus S-1 chemotherapy. 
Our study showed no relationship between 
OPRT and DPYD SNPs and S-1 treatment benefit, 
only the TS 5’UTR SNP predicted benefit from S-1 
adjuvant chemotherapy. This is in contrast to 
previous studies which suggested that protein, 
mRNA, or genetic polymorphism of TS (8-14), DPYD 
(8-10), and OPRT (10-12, 14-16) were predictors of 
response to 5-FU based chemotherapy. However, 
most previous studies did not have a 
non-chemotherapy control arm and thus were not 
able to distinguish between prognostic and predictive 
value of a biomarker or suffered from relatively small 
sample size. Our study is the first to clarify the 
predictive and prognostic impact of these enzyme 
SNPs on S-1.  
 
 
Figure 2. The results of the survival analyses are illustrated using a Forest plot of hazard ratios 
 
Figure 3. The results are illustrated in a Forest plot of hazard ratios 
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TS is an enzyme which catalyzes the methylation 
of fluoro-dUMP to dTMP, an essential precursor for 
DNA synthesis (36). 5-FU inhibits TS activity and 
blocks DNA synthesis (18). It is thus biologically 
plausible that S-1 (a 5-FU prodrug) efficacy might also 
be influenced by TS activity. The promoter enhancer 
region of TS gene is polymorphic, containing a double 
(2R) or triple (3R) tandem repeat known to be 
involved in the translational auto-regulation 
mechanism of TS expression (37). Previous 
investigators reported that 2R/2R, 2R/3C, and 3C/3C 
type of TS polymorphisms were related with better 
survival in colorectal and gastric cancer patients 
receiving fluoropyrimidine (38). However, their study 
did not include a surgery alone group and thus 
cannot distinguish between prognostic and predictive 
value of the SNP. There is currently no study 
published investigating a relationship between TS 
polymorphism and S-1 efficacy. The present study 
was able to clarify that TS 5’UTR polymorphisms 
have no prognostic value in Japanese gastric cancer 
patients (e.g. do not influence the survival in the 
surgery alone group) but does predict benefit from 
adjuvant S-1 treatment depending on the SNP 
subtype of TS 5’UTR. This finding, if replicated in a 
second independent series, could indicate that 
determination of the TS 5’UTR SNP status which 
would be possible in any normal tissue including a 
routine blood sample might be a useful marker to 
stratify patients for adjuvant S-1 therapy and/or other 
therapy options. 
It has been shown recently that classifying 
gastric cancer based on their RNA expression 
signature into G-INT and G-DIFF identifies groups of 
patients with different prognosis (28). Moreover, the 
genomic subtype seemed to predict benefit from 
adjuvant 5-FU based chemotherapy (28). However, 
when using the same classifier in the present study, 
the genomic classifier did neither predict patient 
prognosis nor benefit from adjuvant S-1. This 
discrepancy could be related to the stage selection 
bias in the current study which included only stage 
II/III gastric cancer patients whereas the previous 
study included all disease stages. Secondly, 
differences in drug efficacy between S-1 and 
‘conventional 5-FU’ have been described for diffuse 
type gastric cancer (39) and might explain the 
different results. 
In addition to the investigations into prognostic 
and predictive marker for S-1 benefit, we also used 
this gastric cancer cohort to explore whether there is 
any indication that patients might benefit from 
potential other cytotoxic drugs such as platinum 
based chemotherapy. Polymorphisms for GSTP-1, 
ERCC1 and XRCC1 have been previously identified as 
potential predictive biomarker for platinum based 
chemotherapy in colon cancer patients (34, 35, 40, 41). 
ERCC1 SNPs have shown to have prognostic and/or 
predictive value in the advanced (metastatic) gastric 
cancer setting (17, 19, 35, 42-44). In the current series, 
SNPs of GSTP-1, ERCC1, and XRCC1 were neither a 
prognosticator nor a predictor for S-1 adjuvant 
chemotherapy suggesting that adding platinum drugs 
to S-1 might improve patient’s prognosis. 
Similarly, we explored whether patients in our 
series would potentially be eligible for RTK targeting 
drug therapy such as HER2 targeting trastuzumab, 
pertuzumab or T-DM1; EGFR targeting 
nimotuzumab, FGFR2 targeting AZD4547 or MET 
targeting rilotumumab or onartuzumab or MEK 
inhibitors which may be attractive therapies for 
KRAS-driven tumors. The present study 
demonstrated that high HER2 RNA expression was 
associated with poor prognosis and low EGFR, high 
HER2 and high MET RNA expression were important 
predictor for S-1 resistance.  
Our data seem to indicate that whereas therapy 
targeting HER2 or MET should not be combined with 
S-1 chemotherapy, a combination of EGFR targeting 
drugs with S-1 chemotherapy might be of added 
value. However, a recent study in a subset of patients 
from the ACTS-GC trial (5) reported that HER2 
‘positivity’ by immunohistochemistry or copy 
number analyses was not a significant prognosticator 
and that neither EGFR nor HER2 status predicted 
benefit from S-1. The results from this study are not 
directly comparable with the current study as 
different methodology (RNA expression level in the 
current study versus protein expression and DNA 
copy number in the previous study) was used to 
establish the HER2/EGFR status of the individual 
case. Ma et al reported a low correlation between 
HER2 protein expression and RNA expression and 
suggested that HER2 protein and RNA may have a 
different clinical role in gastric cancer patients (45). 
On the other hand, there is currently no information 
available about the relationship between RNA and 
protein expression levels in EGFR in gastric cancer.  
The present study has some limitations. This is a 
retrospective, single center case-control study with no 
treatment randomization. Thus, in contrast to the 
results from the ACTS-GC trial, the univariate overall 
survival curves were similar between the S-1 group 
and surgery alone group in the current study. 
However, the hazard ratio was almost identical to that 
observed in S-1 arm of ACTS phase III study when the 
survival was adjusted by Cox’s multivariate analysis. 
In addition, the present study was only analyzed the 
Eastern cohort. Therefore, the further study should 
focus on the Western cohort. Furthermore, our study 
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results require validation in a second independent 
cohort of gastric cancer patients treated with adjuvant 
S-1 which was not achievable within the current study 
cohort due to its sample size.  
In conclusion, this is the first comprehensive 
biomarker analysis comparing biomarker status in 
stage II/III gastric cancer patients treated with 
surgery alone to those treated with surgery plus 
adjuvant S-1 chemotherapy. We identified several 
candidate markers such as HER2, EGFR, MET RNA 
expression and TS 5’UTR SNP which are able to 
identify patients with a high risk of recurrence and/or 
no potential benefit from adjuvant S-1 therapy. The 
findings of this study may potentially inform future 
trial design to test platinum drugs and targeting 
agents after biomarker stratification in order to 
improve survival of Japanese stage II/III gastric 
cancer. The promising results from this 
comprehensive but exploratory biomarker analyses 
require validation in a second series before clinical 
application.  
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